Mondo News
    What's Hot
    All

    Looming Retraction Casts Shadow Over Ranga Dias and Study of Superconductors

    All

    Queen Elizabeth II’s death sparks Twitter outages in US, several countries, users report

    All

    California school district to vote on whether high-speed broadband is a human right

    • About Us
    • Contact us
    • Privacy Policy
    • Terms & Conditions
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Mondo News
    • Home
    • Technology

      How MrBeast’s AI deepfake ads appeared on TikTok

      October 4, 2023

      Spotify adds 150,000 audiobooks to premium subscription

      October 4, 2023

      In the latest cruise incident, a pedestrian is seen on video being hit by a human-driven car and then being run over by a robotaxi.

      October 4, 2023

      Electric Hydrogen is the first unicorn in the green hydrogen industry

      October 4, 2023

      Krafton India launches gaming incubator to expand local ecosystem

      October 4, 2023
    • Science

      These are the best ways to care for your microbiome and stay healthy as you age

      October 4, 2023

      Scientists have just figured out how cats purr

      October 4, 2023

      Why we know so little about cannabis – and why scientists are concerned

      October 4, 2023

      Fat Bear Week: How Alaska’s brown bears nearly doubled in size

      October 4, 2023

      David Sacks Explains How Sam Altman Will Own Most of OpenAI

      October 2, 2023
    • Blockchain

      Protecting Wealth in the Digital Age – Blockchain News, Opinions, TV, Jobs

      October 4, 2023

      “Impact on the Economy and Cryptocurrency Market” – Blockchain News, Opinion, TV, Jobs

      October 4, 2023

      Challenging the Meme Coin Market with a Billion Dollar Vision – Blockchain News, Opinion, TV, Jobs

      October 4, 2023

      BTC Price Soars Despite SEC Delays Some ETF Decisions – Blockchain News, Opinion, TV, Jobs

      October 4, 2023

      Microsoft’s Future Nuclear Powered AI Data Centers

      October 2, 2023
    • All

      These are the best ways to care for your microbiome and stay healthy as you age

      October 4, 2023

      Protecting Wealth in the Digital Age – Blockchain News, Opinions, TV, Jobs

      October 4, 2023

      How MrBeast’s AI deepfake ads appeared on TikTok

      October 4, 2023

      Scientists have just figured out how cats purr

      October 4, 2023

      “Impact on the Economy and Cryptocurrency Market” – Blockchain News, Opinion, TV, Jobs

      October 4, 2023
    Mondo News
    You are at:Home»All»U.S. Health Officials Question AstraZeneca Vaccine Trial Results
    23virus-astrazeneca1-articleLarge.jpgaqualityeq75ampampdautoeqwebpampampddisableequpscale
    All March 23, 2021

    U.S. Health Officials Question AstraZeneca Vaccine Trial Results

    Share
    Facebook Twitter LinkedIn Pinterest Email

    According to federal officials, an independent panel of medical experts said the promising results announced by the company on Monday may have relied on “outdated information.”

    Federal health officials said Tuesday that the encouraging results that AstraZeneca announced about its Covid-19 vaccine may have been based on outdated and incomplete information about the vaccine’s effectiveness, an extraordinary blow to the credibility of an already embattled vaccine.

    The public airing of a conflict between a pharmaceutical company and a board overseeing a clinical trial is highly unusual. It is almost certain to trigger extra scrutiny of the vaccine by the Food and Drug Administration and other regulators if AstraZeneca seeks emergency authorization of its vaccine in the United States.

    The friction with the independent monitoring board revolved around how AstraZeneca was determining whether participants in the clinical trial had possible or actual cases of Covid-19, according to a person familiar with the situation. The independent monitoring board twice pushed AstraZeneca to take a more rigorous approach, telling the company it had sufficient information to determine how many trial participants had the disease. That had the potential to reduce the vaccine’s apparent effectiveness.

    But AstraZeneca unveiled its interim results on Monday without conducting the full analysis the board requested, possibly casting its vaccine in an overly favorable light.

    The news sent AstraZeneca shares up about 4 percent on Monday.

    But members of the independent monitoring board were surprised by the company’s announcement. “They got concerned and wrote a rather harsh note to them and with a copy to me, saying that in fact they felt that the data that was in the press release were somewhat outdated and might in fact be misleading a bit and wanted them to straighten it out,” said Dr. Fauci, who runs the National Institute of Allergy and Infectious Diseases.

    That prompted the overnight statement from the infectious-disease institute, which is part of the National Institutes of Health.

    AstraZeneca’s stock fell more than 3.5 percent in early trading on Tuesday.

    Companies sponsoring drug or vaccine trials typically wait for the monitoring board to review analyses and conclude that the study has yielded an answer before they announce trial results.

    Company executives do not see the results of the study until the monitoring board reports their study data back to the company. The monitoring board ultimately conveyed the results of the study to AstraZeneca in a meeting over the weekend, leading to the company’s announcement Monday morning.

    The monitoring board’s slow progress fueled concerns among federal officials that AstraZeneca may have been sitting on the data or that the monitoring board had concerns about the way the data it was reviewing had been presented.

    An AstraZeneca spokeswoman, whom the company declined to name, said on Friday that it was “completely incorrect” that the trial data had formatting problems or had not been submitted to the monitoring board in a clean fashion.

    “As is often the case,” the spokeswoman said, monitoring boards “can request new or clarifying analyses of data from the trial. This would enable them to ensure the robustness of their determinations.”

    The national institute’s statement, issued shortly after midnight, stunned experts. Dr. Eric Topol, a clinical trials expert at Scripps Research in San Diego, said it was “highly irregular” to see such a public display of friction between a monitoring board and a study sponsor, which are typically in close concordance.

    “I’ve never seen anything like this,” he said. “It’s so, so troubling.”

    That U.S. trial, which involved more than 32,000 participants, was the largest test of its kind for the shot. The results AstraZeneca released on Monday were from an interim look at the data after 141 Covid-19 cases had turned up among volunteers.

    The company had not disclosed until Tuesday how up-to-date those data were. That information is important, because sometimes a more current look at clinical trial results can present a different effectiveness and safety.

    If the analysis was conducted on data from a month or two ago, it is possible that a more current look would present a different picture of the vaccine’s effectiveness and safety. The company has said it will provide the F.D.A. with a more comprehensive, recent set of data than what it disclosed on Monday. Although no clinical trial is large enough to rule out extremely rare side effects, AstraZeneca reported that its study turned up no serious safety issues.

    Even so, the better-than-expected results were seen as a heartening turn for AstraZeneca’s shot, whose low cost and simple storage requirements have made it a vital piece of the drive to vaccinate the world.

    AstraZeneca said on Monday that it would continue to analyze the new data and prepare to apply in the coming weeks for emergency authorization in the United States. The vaccine has already been approved in more than 70 countries, but clearance from American regulators would bolster its global reputation.

    Last summer, at least some top F.D.A. officials learned only from news reports that AstraZeneca had paused its Phase 2/3 vaccine trial in Britain after a participant developed neurological symptoms. Then in September, after another participant in the British study fell ill with similar symptoms, AstraZeneca halted its trials globally but failed to promptly notify the U.S. authorities.

    The U.S. study was ultimately paused for seven weeks last fall, in part because AstraZeneca was slow to provide the F.D.A. with evidence that the vaccine had not caused the neurological symptoms. Investigators ultimately concluded that the illnesses could not be linked to the vaccine. Still, the delay was a key reason that AstraZeneca fell so far behind the three other manufacturers whose vaccines have been granted emergency authorization in the United States.

    Category: Science

    Source: New York Times

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleStruggling with COVID fatigue? Citigroup will roll out ‘Zoom Free Fridays’ to give workers a break
    Next Article How Netflix is aiming at kids and families to fend off Disney, other streaming rivals

    Related Posts

    All

    These are the best ways to care for your microbiome and stay healthy as you age

    All

    Protecting Wealth in the Digital Age – Blockchain News, Opinions, TV, Jobs

    All

    How MrBeast’s AI deepfake ads appeared on TikTok

    All

    Scientists have just figured out how cats purr

    All

    “Impact on the Economy and Cryptocurrency Market” – Blockchain News, Opinion, TV, Jobs

    Science

    Why we know so little about cannabis – and why scientists are concerned

    Science

    Fat Bear Week: How Alaska’s brown bears nearly doubled in size

    All

    Microsoft’s Future Nuclear Powered AI Data Centers

    Leave A Reply Cancel Reply

    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • Pinterest
    Quote of the day

    A man on a horse is spiritually as well as physically bigger than a man on foot.

    John Steinbeck


    Exchange Rate

    Exchange Rate EUR: Wed, 4 Oct.

    Top Insights
    All

    Forget to cancel your free trial? 5 silly ways you waste money in your tech life

    All

    Webb Detects Crucial Carbon Molecule in Protoplanetary Disk

    All

    Amazon cloud outage hits websites and streaming apps

    about after amazon apple bezos biden billion bitcoin california change china climate coronavirus could covid earth facebook fight first flight google launch million online other pandemic people plans research rover scientists social space spacex study tesla their these tiktok twitter vaccine vaccines workers world years

    October 2023
    M T W T F S S
     1
    2345678
    9101112131415
    16171819202122
    23242526272829
    3031  
    « Sep    
    Categories
    • All (18,816)
    • Blockchain (818)
    • Science (7,367)
    • Technology (10,667)
    Tags
    about after amazon apple bezos biden billion bitcoin california change china climate coronavirus could covid earth facebook fight first flight google launch million online other pandemic people plans research rover scientists social space spacex study tesla their these tiktok twitter vaccine vaccines workers world years
    Top Posts

    Amazon Prevails Over Reliance in India’s Supreme Court

    August 6, 2021

    Done with Facebook? Here’s how to deactivate or permanently delete your Facebook account

    September 24, 2021

    Climate change in India: Teen inventor’s solar-powered ironing cart

    October 14, 2021

    Mondo News is a Professional Technology & Science Blog. Here we will provide you with only exciting content that you will enjoy and find useful. We’re working to turn our passion into a successful website. We hope you enjoy our Content as much as we enjoy offering them to you.

    Facebook X (Twitter) Instagram Pinterest
    Categories
    • All (18,816)
    • Blockchain (818)
    • Science (7,367)
    • Technology (10,667)
    Most Popular
    All

    The new Mac Mini M2 is the best Mac for the money

    All

    Chinese ‘kissing’ device with ‘real-life silicon lips’ panned as creepy: ‘Where’s the tongue?’

    © 2023 Mondo News.
    • Home
    • About Us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in .

    Ad Blocker Enabled!
    Ad Blocker Enabled!
    Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.
    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.